Pages that link to "Q39044979"
Jump to navigation
Jump to search
The following pages link to Rb loss is characteristic of prostatic small cell neuroendocrine carcinoma (Q39044979):
Displaying 50 items.
- The importance of DNA methylation in prostate cancer development (Q26749545) (← links)
- Resistance to Novel Antiandrogen Therapies in Metastatic Castration-Resistant Prostate Cancer (Q26751237) (← links)
- Molecular aspects of prostate cancer with neuroendocrine differentiation (Q26752910) (← links)
- Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer (Q26777310) (← links)
- Origins, genetic landscape, and emerging therapies of small cell lung cancer (Q26798218) (← links)
- Transformation from non-small-cell lung cancer to small-cell lung cancer: molecular drivers and cells of origin (Q26826437) (← links)
- The many faces of neuroendocrine differentiation in prostate cancer progression (Q26992049) (← links)
- Distinct genetic alterations in small cell carcinoma from different anatomic sites (Q27008242) (← links)
- Targeting the adaptive molecular landscape of castration-resistant prostate cancer (Q27022821) (← links)
- Novel Insights into Molecular Indicators of Response and Resistance to Modern Androgen-Axis Therapies in Prostate Cancer (Q28067556) (← links)
- N-Myc Induces an EZH2-Mediated Transcriptional Program Driving Neuroendocrine Prostate Cancer (Q28771715) (← links)
- Correlation of PSMA-Targeted 18F-DCFPyL PET/CT Findings With Immunohistochemical and Genomic Data in a Patient With Metastatic Neuroendocrine Prostate Cancer (Q31137270) (← links)
- Aggressive variants of castration-resistant prostate cancer (Q33693256) (← links)
- EMT and MET: necessary or permissive for metastasis? (Q33869775) (← links)
- Molecular pathways and targets in prostate cancer (Q34365632) (← links)
- A systems genetics approach identifies CXCL14, ITGAX, and LPCAT2 as novel aggressive prostate cancer susceptibility genes. (Q34549577) (← links)
- Polycomb-mediated silencing in neuroendocrine prostate cancer. (Q35336915) (← links)
- Frequent MED12 mutations in phyllodes tumours of the breast (Q35603644) (← links)
- Integrative molecular profiling of routine clinical prostate cancer specimens. (Q35892022) (← links)
- Neuroendocrine Tumors of the Prostate: Emerging Insights from Molecular Data and Updates to the 2016 World Health Organization Classification (Q35925835) (← links)
- N-Myc Drives Neuroendocrine Prostate Cancer Initiated from Human Prostate Epithelial Cells (Q35980945) (← links)
- Comprehensive serial molecular profiling of an "N of 1" exceptional non-responder with metastatic prostate cancer progressing to small cell carcinoma on treatment (Q36131601) (← links)
- Androgen Receptor-Dependent and -Independent Mechanisms Involved in Prostate Cancer Therapy Resistance. (Q36398998) (← links)
- Flavokawain A induces deNEDDylation and Skp2 degradation leading to inhibition of tumorigenesis and cancer progression in the TRAMP transgenic mouse model. (Q36561595) (← links)
- Translational and clinical implications of the genetic landscape of prostate cancer (Q37270512) (← links)
- Substantial interindividual and limited intraindividual genomic diversity among tumors from men with metastatic prostate cancer (Q37302524) (← links)
- GRK3 is a direct target of CREB activation and regulates neuroendocrine differentiation of prostate cancer cells. (Q37564369) (← links)
- SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer (Q37595372) (← links)
- Circulating tumor cells capture disease evolution in advanced prostate cancer. (Q37661448) (← links)
- Amplification of MUC1 in prostate cancer metastasis and CRPC development (Q37696276) (← links)
- Androgen receptor-dependent and -independent mechanisms driving prostate cancer progression: Opportunities for therapeutic targeting from multiple angles (Q37709535) (← links)
- Models of neuroendocrine prostate cancer (Q38263146) (← links)
- Genitourinary small cell malignancies: prostate and bladder (Q38352874) (← links)
- Targeting neuroendocrine prostate cancer: molecular and clinical perspectives (Q38362686) (← links)
- Multidisciplinary intervention of early, lethal metastatic prostate cancer: Report from the 2015 Coffey-Holden Prostate Cancer Academy Meeting (Q38610286) (← links)
- Epithelial-mesenchymal transition in prostatic disease (Q38628753) (← links)
- The selective PI3Kα inhibitor BYL719 as a novel therapeutic option for neuroendocrine tumors: Results from multiple cell line models. (Q38695102) (← links)
- Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance (Q38722705) (← links)
- RB Loss Promotes Prostate Cancer Metastasis (Q38727367) (← links)
- Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer (Q38768101) (← links)
- Neuroendocrine Tumor of the Ureter: A Zebra Among Horses (Q38792928) (← links)
- Conversion of Prostate Adenocarcinoma to Small Cell Carcinoma-Like by Reprogramming (Q38803108) (← links)
- miR-449a enhances radiosensitivity through modulating pRb/E2F1 in prostate cancer cells (Q38823185) (← links)
- GNL3 and SKA3 are novel prostate cancer metastasis susceptibility genes (Q38830853) (← links)
- Emerging trends in the evaluation and management of small cell prostate cancer: a clinical and molecular perspective. (Q38930155) (← links)
- The molecular underpinnings of prostate cancer: impacts on management and pathology practice (Q38983790) (← links)
- Strategies to avoid treatment-induced lineage crisis in advanced prostate cancer (Q39016544) (← links)
- Combined Tumor Suppressor Defects Characterize Clinically Defined Aggressive Variant Prostate Cancers (Q39051337) (← links)
- Ablating all three retinoblastoma family members in mouse lung leads to neuroendocrine tumor formation. (Q39102749) (← links)
- Molecular mechanisms of therapy resistance in solid tumors: chasing "moving" targets (Q39172297) (← links)